Sirturo and Breastfeeding
Although no human studies have been done on using Sirturo (bedaquiline) while breastfeeding, the drug has been shown to pass through breast milk in rats. Because of the potential for serious side effects, the manufacturer recommends that women either take Sirturo or breastfeed, but not do both. Talk to your healthcare provider about the potential risks that may apply to your situation.
Sirturo™ (bedaquiline) is a prescription medication used to treat people with tuberculosis of the lungs that is resistant to at least two of the primary medications used to treat this condition. It is reserved for use in people who have very few other treatment options.
At this time, it is not known if Sirturo passes through breast milk in humans. The manufacturer recommends that women either choose to breastfeed or choose to take Sirturo, but not do both. Therefore, if you are breastfeeding or plan to start, talk with your healthcare provider before taking this medication.
In animal studies, Sirturo was shown to pass through the breast milk of rats. Drug levels in the rat breast milk were higher than in the mother rats' bloodstream.
Sirturo has not been studied in breastfeeding women. Therefore, it is not known for certain how much of the medication would be found in human breast milk or whether the drug would harm a nursing infant.
Sirturo is associated with potentially serious side effects, including liver and heart rhythm problems. Because there is the potential that the drug could pass through breast milk and cause these and other problems in a nursing child, the manufacturer recommends the medication not be used in women who are breastfeeding.